Sami Uwaydat
Concepts (288)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinal Diseases | 11 | 2024 | 53 | 5.290 |
Why?
| | Eye Injuries | 5 | 2024 | 25 | 3.090 |
Why?
| | Visual Acuity | 15 | 2024 | 144 | 2.840 |
Why?
| | Vitrectomy | 11 | 2024 | 61 | 2.390 |
Why?
| | Tomography, Optical Coherence | 18 | 2024 | 110 | 2.310 |
Why?
| | Retina | 8 | 2024 | 60 | 1.940 |
Why?
| | Endophthalmitis | 4 | 2022 | 26 | 1.890 |
Why?
| | Diabetic Retinopathy | 4 | 2026 | 43 | 1.890 |
Why?
| | Macular Degeneration | 3 | 2024 | 28 | 1.770 |
Why?
| | Retinal Perforations | 3 | 2024 | 9 | 1.730 |
Why?
| | Macular Edema | 4 | 2023 | 30 | 1.510 |
Why?
| | Retinal Degeneration | 4 | 2022 | 9 | 1.500 |
Why?
| | Drug Implants | 5 | 2020 | 35 | 1.470 |
Why?
| | Eye Proteins | 3 | 2023 | 16 | 1.460 |
Why?
| | Chorioretinitis | 2 | 2022 | 10 | 1.430 |
Why?
| | Retinal Dystrophies | 2 | 2021 | 5 | 1.430 |
Why?
| | Fungemia | 2 | 2022 | 38 | 1.410 |
Why?
| | Eye Infections, Fungal | 2 | 2022 | 20 | 1.400 |
Why?
| | Eye Diseases | 4 | 2023 | 33 | 1.260 |
Why?
| | Eye Infections, Bacterial | 3 | 2024 | 29 | 1.250 |
Why?
| | Dexamethasone | 4 | 2020 | 434 | 1.230 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2026 | 570 | 1.110 |
Why?
| | Glaucoma, Open-Angle | 2 | 2026 | 24 | 1.070 |
Why?
| | Humans | 61 | 2026 | 52441 | 1.070 |
Why?
| | Fluorescein Angiography | 8 | 2024 | 35 | 1.020 |
Why?
| | Fundus Oculi | 7 | 2024 | 24 | 0.910 |
Why?
| | Glucocorticoids | 5 | 2020 | 234 | 0.880 |
Why?
| | Syphilis Serodiagnosis | 1 | 2024 | 4 | 0.870 |
Why?
| | Treponema pallidum | 1 | 2024 | 9 | 0.870 |
Why?
| | Myopia, Degenerative | 1 | 2024 | 1 | 0.860 |
Why?
| | Burns, Chemical | 1 | 2024 | 9 | 0.850 |
Why?
| | Amnion | 1 | 2024 | 13 | 0.850 |
Why?
| | Syphilis | 1 | 2024 | 20 | 0.840 |
Why?
| | Retinal Vein Occlusion | 2 | 2023 | 13 | 0.820 |
Why?
| | Intraoperative Complications | 4 | 2024 | 113 | 0.750 |
Why?
| | Charcot-Marie-Tooth Disease | 1 | 2022 | 7 | 0.750 |
Why?
| | Optic Atrophy | 1 | 2022 | 13 | 0.740 |
Why?
| | Retrospective Studies | 19 | 2026 | 6694 | 0.740 |
Why?
| | Genetic Testing | 2 | 2020 | 130 | 0.740 |
Why?
| | Intraocular Pressure | 4 | 2026 | 61 | 0.710 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 217 | 0.700 |
Why?
| | Giant Cell Arteritis | 1 | 2021 | 14 | 0.700 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2021 | 8 | 0.690 |
Why?
| | Databases, Factual | 2 | 2024 | 721 | 0.690 |
Why?
| | Laser Coagulation | 1 | 2021 | 26 | 0.680 |
Why?
| | Retinal Pigment Epithelium | 2 | 2022 | 14 | 0.680 |
Why?
| | Manikins | 1 | 2021 | 32 | 0.680 |
Why?
| | Middle Aged | 21 | 2026 | 13133 | 0.680 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 30 | 0.670 |
Why?
| | Electroretinography | 7 | 2023 | 17 | 0.670 |
Why?
| | Multiple Sclerosis | 1 | 2021 | 72 | 0.660 |
Why?
| | Candidiasis | 1 | 2021 | 112 | 0.650 |
Why?
| | Diabetes Mellitus | 1 | 2024 | 318 | 0.650 |
Why?
| | Wounds, Nonpenetrating | 1 | 2021 | 84 | 0.650 |
Why?
| | Choroidal Neovascularization | 2 | 2019 | 18 | 0.650 |
Why?
| | Intravitreal Injections | 7 | 2023 | 33 | 0.650 |
Why?
| | Anterior Chamber | 2 | 2023 | 5 | 0.630 |
Why?
| | Surgical Instruments | 1 | 2019 | 29 | 0.620 |
Why?
| | Endotamponade | 2 | 2017 | 10 | 0.580 |
Why?
| | Gaucher Disease | 1 | 2018 | 17 | 0.570 |
Why?
| | Eyelashes | 1 | 2018 | 3 | 0.560 |
Why?
| | Male | 30 | 2026 | 26874 | 0.560 |
Why?
| | Eyelid Diseases | 1 | 2018 | 11 | 0.560 |
Why?
| | Sulfur Hexafluoride | 1 | 2017 | 3 | 0.550 |
Why?
| | Female | 25 | 2026 | 28277 | 0.540 |
Why?
| | Eye Diseases, Hereditary | 1 | 2017 | 5 | 0.530 |
Why?
| | Inheritance Patterns | 1 | 2017 | 22 | 0.530 |
Why?
| | Incidence | 5 | 2026 | 1096 | 0.520 |
Why?
| | Phacoemulsification | 4 | 2024 | 36 | 0.510 |
Why?
| | Urinary Catheters | 1 | 2016 | 4 | 0.500 |
Why?
| | Lenses | 1 | 2016 | 4 | 0.490 |
Why?
| | Suction | 1 | 2016 | 22 | 0.490 |
Why?
| | Mutation | 3 | 2022 | 1331 | 0.480 |
Why?
| | Eye Injuries, Penetrating | 2 | 2015 | 12 | 0.460 |
Why?
| | Bacillaceae | 1 | 2015 | 2 | 0.460 |
Why?
| | Aspirin | 1 | 2016 | 122 | 0.450 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 123 | 0.450 |
Why?
| | Adult | 17 | 2026 | 14205 | 0.450 |
Why?
| | Aged | 14 | 2026 | 10242 | 0.440 |
Why?
| | Choroid Neoplasms | 1 | 2014 | 6 | 0.430 |
Why?
| | Ocular Hypotension | 1 | 2013 | 2 | 0.420 |
Why?
| | Wound Healing | 2 | 2016 | 223 | 0.420 |
Why?
| | Antibodies, Monoclonal | 1 | 2018 | 475 | 0.420 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 26 | 0.420 |
Why?
| | Viscosupplements | 1 | 2013 | 14 | 0.420 |
Why?
| | Head Injuries, Closed | 1 | 2013 | 6 | 0.420 |
Why?
| | Hyaluronic Acid | 1 | 2013 | 38 | 0.410 |
Why?
| | Disease Models, Animal | 2 | 2016 | 1483 | 0.400 |
Why?
| | Retinitis Pigmentosa | 2 | 2023 | 8 | 0.400 |
Why?
| | Physicians, Primary Care | 1 | 2013 | 43 | 0.400 |
Why?
| | Sulfonamides | 1 | 2014 | 137 | 0.390 |
Why?
| | Diabetes Complications | 1 | 2013 | 124 | 0.380 |
Why?
| | Retinal Detachment | 2 | 2023 | 26 | 0.370 |
Why?
| | Skin Neoplasms | 2 | 2014 | 496 | 0.370 |
Why?
| | Acute Disease | 3 | 2023 | 384 | 0.370 |
Why?
| | Pedigree | 3 | 2023 | 126 | 0.360 |
Why?
| | Honey | 1 | 2011 | 6 | 0.360 |
Why?
| | Keratitis | 1 | 2011 | 12 | 0.360 |
Why?
| | Clinical Competence | 2 | 2013 | 405 | 0.350 |
Why?
| | Papilledema | 2 | 2022 | 27 | 0.350 |
Why?
| | Indoles | 1 | 2014 | 283 | 0.350 |
Why?
| | Pseudomonas Infections | 1 | 2011 | 55 | 0.350 |
Why?
| | Risk Factors | 6 | 2026 | 3971 | 0.350 |
Why?
| | Melanoma | 1 | 2014 | 272 | 0.340 |
Why?
| | Panuveitis | 2 | 2021 | 6 | 0.340 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 358 | 0.320 |
Why?
| | Antineoplastic Agents | 2 | 2018 | 1216 | 0.310 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2013 | 504 | 0.300 |
Why?
| | Retinal Vessels | 3 | 2024 | 18 | 0.300 |
Why?
| | Scleral Buckling | 2 | 2023 | 5 | 0.280 |
Why?
| | Phenotype | 2 | 2021 | 792 | 0.280 |
Why?
| | Fovea Centralis | 3 | 2022 | 6 | 0.270 |
Why?
| | Ophthalmology | 3 | 2018 | 34 | 0.270 |
Why?
| | Equipment Contamination | 1 | 2007 | 20 | 0.260 |
Why?
| | Microscopy | 1 | 2007 | 47 | 0.260 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2007 | 21 | 0.260 |
Why?
| | Child, Preschool | 5 | 2024 | 4046 | 0.250 |
Why?
| | Ocular Hypertension | 1 | 2026 | 9 | 0.240 |
Why?
| | Lens Subluxation | 1 | 2024 | 2 | 0.220 |
Why?
| | Fractals | 1 | 2024 | 9 | 0.220 |
Why?
| | Limbus Corneae | 1 | 2024 | 8 | 0.220 |
Why?
| | Reagins | 1 | 2024 | 3 | 0.220 |
Why?
| | Posterior Eye Segment | 1 | 2024 | 3 | 0.220 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 29 | 0.210 |
Why?
| | Subretinal Fluid | 1 | 2023 | 2 | 0.210 |
Why?
| | Paracentesis | 1 | 2023 | 13 | 0.210 |
Why?
| | Choroid | 2 | 2024 | 14 | 0.210 |
Why?
| | Follow-Up Studies | 7 | 2024 | 2294 | 0.210 |
Why?
| | Immunoglobulin G | 1 | 2024 | 193 | 0.200 |
Why?
| | Retinoschisis | 1 | 2023 | 3 | 0.200 |
Why?
| | Child | 7 | 2024 | 7194 | 0.200 |
Why?
| | Hemoglobin C | 1 | 2023 | 6 | 0.200 |
Why?
| | Optic Nerve Injuries | 1 | 2022 | 8 | 0.200 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2020 | 186 | 0.190 |
Why?
| | Thionucleotides | 1 | 2002 | 11 | 0.190 |
Why?
| | Scotoma | 1 | 2021 | 6 | 0.180 |
Why?
| | Macula Lutea | 1 | 2021 | 3 | 0.180 |
Why?
| | Albinism, Oculocutaneous | 1 | 2021 | 2 | 0.180 |
Why?
| | Vision Disorders | 2 | 2022 | 61 | 0.180 |
Why?
| | Temporal Arteries | 1 | 2021 | 16 | 0.180 |
Why?
| | Ophthalmoscopy | 1 | 2021 | 17 | 0.170 |
Why?
| | Young Adult | 4 | 2022 | 4346 | 0.170 |
Why?
| | Choroiditis | 1 | 2020 | 9 | 0.170 |
Why?
| | Antiviral Agents | 1 | 2002 | 173 | 0.170 |
Why?
| | Exons | 1 | 2021 | 101 | 0.170 |
Why?
| | Internship and Residency | 2 | 2013 | 438 | 0.170 |
Why?
| | Infant | 3 | 2024 | 3709 | 0.160 |
Why?
| | Eye Abnormalities | 1 | 2020 | 24 | 0.160 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2000 | 2 | 0.160 |
Why?
| | Conjunctival Diseases | 1 | 2000 | 4 | 0.160 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 521 | 0.160 |
Why?
| | Eyeglasses | 1 | 2019 | 9 | 0.160 |
Why?
| | Disease Management | 1 | 2021 | 185 | 0.160 |
Why?
| | Vitreoretinal Surgery | 1 | 2019 | 8 | 0.160 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 178 | 0.160 |
Why?
| | Intraoperative Period | 1 | 2019 | 46 | 0.160 |
Why?
| | Optic Disk | 1 | 2019 | 20 | 0.150 |
Why?
| | Crohn Disease | 1 | 2020 | 115 | 0.150 |
Why?
| | Pandemics | 1 | 2024 | 580 | 0.150 |
Why?
| | United States | 3 | 2026 | 5215 | 0.150 |
Why?
| | Biopsy | 1 | 2021 | 594 | 0.150 |
Why?
| | Laser Therapy | 1 | 2019 | 74 | 0.150 |
Why?
| | Amaurosis Fugax | 1 | 2018 | 3 | 0.150 |
Why?
| | Vision, Ocular | 1 | 2018 | 10 | 0.150 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 150 | 0.150 |
Why?
| | Glucosylceramidase | 1 | 2018 | 8 | 0.140 |
Why?
| | Retinal Artery Occlusion | 1 | 2018 | 11 | 0.140 |
Why?
| | Enzyme Replacement Therapy | 1 | 2018 | 17 | 0.140 |
Why?
| | Visual Fields | 1 | 2018 | 39 | 0.140 |
Why?
| | Vascular Malformations | 1 | 2020 | 105 | 0.140 |
Why?
| | Fluocinolone Acetonide | 1 | 2017 | 5 | 0.140 |
Why?
| | Prone Position | 1 | 2017 | 29 | 0.140 |
Why?
| | Thrombolytic Therapy | 1 | 2018 | 113 | 0.130 |
Why?
| | Genes, Recessive | 1 | 2017 | 16 | 0.130 |
Why?
| | Consanguinity | 1 | 2017 | 18 | 0.130 |
Why?
| | Uveitis | 1 | 2017 | 21 | 0.130 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 131 | 0.130 |
Why?
| | Heterozygote | 1 | 2017 | 89 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2018 | 490 | 0.130 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 179 | 0.130 |
Why?
| | Adolescent | 4 | 2022 | 6713 | 0.130 |
Why?
| | Air | 1 | 2016 | 22 | 0.130 |
Why?
| | Minerals | 1 | 2016 | 26 | 0.130 |
Why?
| | Genetic Association Studies | 1 | 2017 | 124 | 0.130 |
Why?
| | Vascular Surgical Procedures | 1 | 2018 | 166 | 0.120 |
Why?
| | Sodium Chloride | 1 | 2016 | 55 | 0.120 |
Why?
| | Patient Selection | 1 | 1998 | 269 | 0.120 |
Why?
| | Acetates | 1 | 2016 | 51 | 0.120 |
Why?
| | Chemokine CCL2 | 1 | 2016 | 65 | 0.120 |
Why?
| | Equipment Failure | 1 | 2016 | 63 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 234 | 0.120 |
Why?
| | Animals | 5 | 2022 | 13485 | 0.120 |
Why?
| | Eye Foreign Bodies | 1 | 2015 | 6 | 0.110 |
Why?
| | Nevus of Ota | 1 | 2014 | 2 | 0.110 |
Why?
| | Scleral Diseases | 1 | 2014 | 2 | 0.110 |
Why?
| | Eye Neoplasms | 1 | 2014 | 8 | 0.110 |
Why?
| | Siblings | 1 | 2014 | 35 | 0.110 |
Why?
| | Liver Neoplasms | 1 | 2018 | 341 | 0.110 |
Why?
| | Vision, Monocular | 1 | 2013 | 1 | 0.110 |
Why?
| | Injections, Intraocular | 1 | 2013 | 2 | 0.110 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2013 | 11 | 0.100 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2014 | 75 | 0.100 |
Why?
| | Cell Line | 1 | 2016 | 1020 | 0.100 |
Why?
| | Molecular Biology | 2 | 2023 | 27 | 0.100 |
Why?
| | GTP-Binding Proteins | 2 | 2023 | 86 | 0.100 |
Why?
| | Treatment Outcome | 4 | 2020 | 5508 | 0.100 |
Why?
| | Activities of Daily Living | 1 | 2013 | 185 | 0.100 |
Why?
| | Postoperative Complications | 2 | 2024 | 1065 | 0.100 |
Why?
| | Autistic Disorder | 1 | 2013 | 125 | 0.090 |
Why?
| | Diet | 1 | 2016 | 591 | 0.090 |
Why?
| | Endotoxins | 1 | 2011 | 23 | 0.090 |
Why?
| | Rats, Inbred Lew | 1 | 2011 | 49 | 0.090 |
Why?
| | Administration, Topical | 1 | 2011 | 62 | 0.090 |
Why?
| | Referral and Consultation | 1 | 2013 | 288 | 0.090 |
Why?
| | Cornea | 1 | 2011 | 53 | 0.090 |
Why?
| | Pseudomonas aeruginosa | 1 | 2011 | 79 | 0.090 |
Why?
| | Membrane Proteins | 2 | 2023 | 344 | 0.080 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 1888 | 0.080 |
Why?
| | Mice | 2 | 2022 | 5899 | 0.080 |
Why?
| | RNA | 1 | 2011 | 174 | 0.080 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 580 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 1507 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 2 | 2020 | 183 | 0.070 |
Why?
| | Cytokines | 1 | 2011 | 622 | 0.070 |
Why?
| | Lens Implantation, Intraocular | 2 | 2018 | 25 | 0.070 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 1677 | 0.070 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2007 | 3 | 0.070 |
Why?
| | Aged, 80 and over | 3 | 2020 | 3449 | 0.070 |
Why?
| | Orbital Cellulitis | 1 | 2007 | 9 | 0.070 |
Why?
| | Corneal Diseases | 1 | 2007 | 15 | 0.070 |
Why?
| | Microsurgery | 1 | 2007 | 32 | 0.070 |
Why?
| | Fungi | 1 | 2007 | 51 | 0.060 |
Why?
| | Cross Infection | 1 | 2007 | 94 | 0.060 |
Why?
| | Lipids | 2 | 2022 | 163 | 0.060 |
Why?
| | Aptamers, Nucleotide | 1 | 2006 | 7 | 0.060 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 171 | 0.060 |
Why?
| | Prosthesis-Related Infections | 1 | 2007 | 108 | 0.060 |
Why?
| | Vitamins | 1 | 2006 | 59 | 0.060 |
Why?
| | Bacteria | 1 | 2007 | 223 | 0.060 |
Why?
| | Vitreous Body | 2 | 2002 | 18 | 0.060 |
Why?
| | Rats | 1 | 2011 | 3228 | 0.060 |
Why?
| | Microvessels | 1 | 2024 | 35 | 0.050 |
Why?
| | Recovery of Function | 1 | 2023 | 201 | 0.050 |
Why?
| | Optic Nerve | 1 | 2022 | 39 | 0.050 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 14 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2024 | 404 | 0.050 |
Why?
| | Cytomegalovirus Retinitis | 1 | 2002 | 2 | 0.050 |
Why?
| | Injections | 1 | 2002 | 60 | 0.050 |
Why?
| | Smoking | 1 | 2006 | 514 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 245 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2007 | 1028 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 255 | 0.040 |
Why?
| | Hypertension | 1 | 2006 | 560 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 609 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2023 | 218 | 0.040 |
Why?
| | Vibration | 1 | 2000 | 14 | 0.040 |
Why?
| | Retinal Artery | 1 | 2000 | 4 | 0.040 |
Why?
| | Retinal Vein | 1 | 2000 | 3 | 0.040 |
Why?
| | Epiretinal Membrane | 1 | 2020 | 10 | 0.040 |
Why?
| | Iris | 1 | 2000 | 6 | 0.040 |
Why?
| | Conjunctiva | 1 | 2000 | 14 | 0.040 |
Why?
| | Healthcare Disparities | 1 | 2023 | 291 | 0.040 |
Why?
| | Cholesterol | 1 | 2000 | 159 | 0.040 |
Why?
| | Fatty Acids | 1 | 2000 | 152 | 0.040 |
Why?
| | Mitochondria | 1 | 2022 | 420 | 0.040 |
Why?
| | Occupational Diseases | 1 | 2000 | 85 | 0.040 |
Why?
| | Triglycerides | 1 | 2000 | 171 | 0.040 |
Why?
| | Equipment Design | 1 | 2019 | 287 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 12 | 0.040 |
Why?
| | State Medicine | 1 | 2018 | 19 | 0.040 |
Why?
| | Developing Countries | 1 | 1998 | 64 | 0.030 |
Why?
| | Time-to-Treatment | 1 | 2018 | 77 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 637 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 136 | 0.030 |
Why?
| | Video Recording | 1 | 2016 | 79 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2018 | 274 | 0.030 |
Why?
| | Prospective Studies | 2 | 2000 | 2433 | 0.030 |
Why?
| | Pilot Projects | 1 | 1998 | 725 | 0.030 |
Why?
| | Time Factors | 1 | 2019 | 2987 | 0.020 |
Why?
| | Electrooculography | 1 | 2007 | 13 | 0.020 |
Why?
| | Inclusion Bodies | 1 | 2007 | 17 | 0.020 |
Why?
| | Lymphocytes | 1 | 2007 | 146 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2007 | 191 | 0.020 |
Why?
| | Fibroblasts | 1 | 2007 | 357 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 1140 | 0.010 |
Why?
| | Corneal Opacity | 1 | 2000 | 3 | 0.010 |
Why?
| | Trabecular Meshwork | 1 | 2000 | 4 | 0.010 |
Why?
| | Pigmentation Disorders | 1 | 2000 | 6 | 0.010 |
Why?
|
|
Uwaydat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|